So there's an issue of identification.
Let me turn a little bit to the other issue that has been raised by the committee and by many of the people who have come before us. There is concern now about the possibility that the diseases are taking on new characteristics and morphing into different, more virulent types of disease, and that those are giving way to the possibility of other diseases of opportunity. Five years ago, we had a certain regime of drugs that were available. We now have a second generation.
Mr. McCool, I'm wondering how much of those second-generation drugs your industry has provided, at their cost, to various regions to alleviate and to bring down the number of cases of individuals afflicted.